Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314234 | 0.77 | MKNK1 (0.47) | MKNK1DYRK1AKLK7SSTR4PDE4A | |
| SCHEMBL22510132 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7SSTR4EGLN2 | |
| SCHEMBL19493139 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7SSTR4PDE4A | |
| SCHEMBL2392859 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7SSTR4EGLN2 | |
| SCHEMBL477032 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7SSTR4PDE4A | |
| SCHEMBL5494796 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7SSTR4PDE4A | |
| SCHEMBL3243144 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7SSTR4PDE4A | |
| SCHEMBL4569227 | 0.75 | SSTR4 (0.49) | MKNK1DYRK1AKLK7SSTR4PDE4A | |
| SCHEMBL18878995 | 0.75 | MKNK1 (0.49) | MKNK1DYRK1AKLK7SSTR4DGAT1 | |
| SCHEMBL6842146 | 0.75 | MKNK1 (0.49) | MKNK1DYRK1AKLK7SSTR4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137329-A1 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| WO-2023159307-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2023-08-31 | — | — | WO | disclosed |
| EP-4212516-A1 | 2-PHENYL-6-HALO-QUINOXALINE DERIVATIVES AS CHAPERONE-MEDIATED AUTOPHAGY (CMA) MODULATORS FOR THE TREATMENT OF PARKINGSON'S DISEASE | Albert Einstein College of Medicine (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023130054-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023114198-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7714319-B2 | Organic thin film transistor | IDEMITSU KOSAN CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20070120111-A1 | Organic thin film transistor | IDEMITSU KOSAN CO., LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | MKNK1 243/4885DYRK1A 560/4885KLK7 4282/4885 |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | MKNK1 33/4885DYRK1A 303/4885KLK7 2304/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | MKNK1 233/4885DYRK1A 2864/4885KLK7 3961/4885 |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | STING1, CGAS, IRF3 | MKNK1 1783/4885DYRK1A 3215/4885KLK7 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.